Growing Cancer Prevalence Fuels Bevacizumab Biosimilars Market Expansion Is Supporting Development Across The Bevacizumab Biosimilars Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Bevacizumab Biosimilars Market During 2026–2030?

The bevacizumab biosimilars market size has experienced robust expansion in recent years. This market is projected to expand from $1.64 billion in 2025 to $1.77 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.5%. Historically, factors such as the patent expiration of reference bevacizumab, an increase in cancer prevalence, the need for economical biologics, governmental support for biosimilars, and progress in recombinant DNA technology have driven this growth.

The bevacizumab biosimilars market size is projected to undergo significant expansion in the coming years, reaching a value of $2.42 billion by 2030, with a compound annual growth rate (CAGR) of 8.2%. This anticipated increase is attributed to a rise in biosimilar approvals, the expansion into developing markets, the integration of AI into drug development processes, a growing inclination towards outpatient oncology care, and strategic collaborations among pharmaceutical firms. Key trends for the forecast period include a greater embrace of biosimilars in oncology, the provision of cost-effective treatment alternatives, an increase in regulatory clearances for biosimilars, the broadening of hospital and retail pharmacy networks, and the proliferation of specialized cancer treatment centers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Influential Factors Are Boosting The Bevacizumab Biosimilars Market Demand?

The increasing occurrence of cancer cases is anticipated to drive expansion in the bevacizumab biosimilar market going forward. Cancer incidence quantifies the new cancer diagnoses within a defined population over a particular timeframe. Bevacizumab, a biologic, functions by blocking tumor angiogenesis, which can lead to reduced tumor size and inhibited growth, and it demonstrates comparable effectiveness and safety to reference biologics when treating individuals with advanced non-small cell lung cancer or metastatic colorectal cancer. As an illustration, in October 2025, according to the NHS England, a UK-based government department, there were 354,820 new cancer diagnoses in England in 2023, which represents an increase of 8,605 from 2022. Consequently, the growing frequency of cancer cases is fueling the bevacizumab biosimilars market.

How Are Different Segment Groups Identified Within The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Which Trends Are Shaping The Bevacizumab Biosimilars Market Landscape?

Major companies within the bevacizumab biosimilars market are concentrating on technological advancements, such as next-generation formulations with expanded indications, to address the growing need for more adaptable and affordable biologic therapies across both oncology and non-oncology applications. These sophisticated formulations adapt the fundamental bevacizumab antibody for new administration routes or indications, allowing for non-cancerous uses (for example, in ophthalmology) or more patient-friendly dosing, while still retaining the same VEGF-neutralizing mechanism employed by traditional intravenous bevacizumab. For instance, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, introduced Versavo (bevacizumab) in the UK. This high-quality biosimilar of Avastin (bevacizumab) is manufactured for oncology applications, thereby making treatments for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more financially attainable for a broader patient population. Versavo is supplied in 100 mg and 400 mg single-use vials, aligning with standard bevacizumab dosing, and offers a biosimilar cost-benefit that assists in reducing the financial burden on healthcare systems and patients reliant on anti-VEGF therapy.

Who Are The Firms Contributing To The Bevacizumab Biosimilars Market Ecosystem?

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Access The Complete Bevacizumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Contributes The Most To The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Bevacizumab Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795